Meningococcal Vaccines Market

Meningococcal Vaccines Market: Infants, Adolescents, and Young Adults Primary Target Groups: Global Industry Analysis (2013 - 2017) & Opportunity Assessment (2018 - 2028)

  • 2018-05-29
  • REP-GB-1252
  • 236 pages
  • Format: PDF/PPT/Excel

An Incisive, In-depth Analysis on the Meningococcal Vaccines Market

This study offers a comprehensive, 360 degree analysis on the Meningococcal Vaccines market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Meningococcal Vaccines market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Key market players are broadening their product range in developed markets like the U.S to demonstrate the impact of meningococcal vaccines in infants and meningococcal carriage in adolescents

The outbreak of meningococcal meningitis is a severe public health concern and while effective and affordable treatment options are available in the global market, the disease has been found to induce a high rate of mortality and create long-term neurological defects in infants and young children. 50% of bacterial meningitis cases are found in children below five years of age. The next age group susceptible to the disease is the 15 – 19 years category. Considering the predominant adverse impact of meningococcal meningitis on the young population, top companies like GlaxoSmithKline are working on expanding their product line – including the addition of new formulations – to cater to this demographic.

Increasing adoption rate among the younger population to be witnessed in the coming years

Growing incidence of meningococcal meningitis among young children and adolescents has prompted the inclusion of meningococcal vaccines in national immunisation programmes by the governments of various countries. Demand for meningococcal vaccines for infants surpasses other age groups. Very recently, a study evaluating the safety and efficacy of a new meningococcal vaccine in adolescents and children indicated a satisfactory short-term safety profile with enhanced levels of immunogenicity. It was also observed that individuals who were administered this vaccine developed immunity levels 9-13 times more than those individuals who were administered regular meningococcal vaccines.

With the outbreak of meningitis threatening the lives of countless young people all over the world, manufacturers are introducing newer molecule formulations and pipeline products in the global market. This is boosting the growth in demand for the various meningococcal vaccines currently being administered across hospitals, clinics, and other global medical facilities.


Lack of awareness of the harmful effects of meningitis on toddlers and young children is challenging growth in adoption of vaccination programmes

Studies indicate that parents of infants and young children are unaware of the disease pathogenesis of meningococcal meningitis and hence do not understand the importance of government initiated meningococcal vaccination programmes. This has eventually led to low adoption of meningococcal vaccines especially in toddlers and children. Consider these statistics:

  • Only 1 in 5 parents (about 21%) are aware of the most common manner in which children contract meningococcal disease

  • More than half (about 54%) of the parents are not aware that there are different strains of meningococcal bacteria that cause meningococcal meningitis

  • Over half (about 52%) of the parents do not know what specific vaccines are included in the immunisation schedule defined by the government in their country of residence

  • 7 out of 10 parents (about 69%) are not clear about the extent of damage caused by meningococcal meningitis

This awareness gap is the main factor responsible for low demand for meningococcal vaccines and this is expected to have a negative impact on revenue growth of the global meningococcal vaccines market. There is a need to initiate community awareness of the disease and the importance of administering prescribed vaccines so as to curb the proliferation of meningococcal meningitis at the global level. This activity can be initiated by government and healthcare organisations in collaboration with hospitals and clinics to educate parents and create the necessary awareness to encourage the adoption of meningococcal vaccines.

This Future Market Insights (FMI) report examines the global meningococcal vaccines market for the period 2013–2028. The primary objective of the report is to offer insights into market opportunity for meningitis vaccines and pipeline developments in the meningitis vaccines market. The global meningitis vaccines market has witnessed spontaneous changes in the immunisation landscape after the launch of new vaccines and initiation of public-private alliances to widen immunisation coverage. Meningococcal disease is prevalent in infants and young children. According to Centre for Disease Control and Prevention (CDC), over half of the bacterial meningitis cases occur in children less than five years of age. Approximately 10%-20% of these patients suffer from the severe consequences of meningitis including permanent damage and disability.

The market for meningococcal vaccines is primarily driven by enhanced access to vaccines in middle income countries, growing investment by manufacturers and governments to expand vaccine production, and mass immunisation campaigns. However, insufficient meningococcal immunisation coverage in low-income countries and restricted access due to stringent regulations are some of the factors limiting revenue growth of the global meningococcal vaccines market.

The global meningococcal vaccines market has been segmented on the basis of:

  • Product Type

  • Age Group

  • Distribution Channel

  • Region

The report analyses the global meningococcal vaccines market in terms of value (US$ Mn). The report begins with the market definition and explains the different types and causes of meningitis, highlighting bacterial meningitis. This section also explains the prevalence of different serogroups of N. meningitides across key regions. The journey of vaccine manufacturing explains the complex chain involving different nodes in the market and highlights how vaccines reach the market. The market viewpoint section includes FMI’s analysis on key trends, drivers, opportunities, trends and macro factors influencing the global market. Opportunity analysis provided in the section better equips clients with crystal clear decision making insights. Pipeline analysis provided in the subsequent section helps clients identify future competitors in the global market.

The report analyses the market based on regions and presents a comprehensive forecast in terms of value (US$ Mn) for the next 10 years. Regions covered in the report include:

  • North America

  • Latin America

  • Western Europe

  • Eastern Europe

  • Asia Pacific Excluding Japan (APEJ)

  • Japan

  • The Middle East and Africa (MEA)

Each of these section analyses the various regional markets by product type, age group, distribution channel and country. Regional introductory sections provide key insights on market dynamics for each region. These sections are mainly designed to provide the current scenario of meningococcal vaccines market and forecast for 2018-2028. A section on representative market participants presents a list of companies operating in each region, competitive landscape and intensity map of their presence in each region.

We have incorporated a robust methodology to substantiate our research

To arrive at the market size, we have used our in-house epidemiology data-based model to estimate the meningococcal vaccines market size. We have adopted the bottom-up approach to forecast the meningococcal vaccines market. Weighted average selling price has been considered to estimate the market size of various product types mentioned in the scope of the study. The country price is captured with the local currency. The local currency figures are then converted to USD to offer forecasts in a consistent currency standard. Furthermore, we have also considered the latest annual exchange rate to reflect the impact of the most recent economic conditions of each assessed country. The forecast presented in the report provides total revenue of currently approved meningococcal vaccine products over 2018–2028. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global market.

In the next section of the report, a ‘Competitive Landscape’ is included to provide report audiences with a dashboard view of the key differentiators among the competitor firms. Market structure analysis provides tier wise breakdown of total market revenue. The section also provides company share analysis and brand share analysis for key market players. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of key providers specific to the various market segments. Detailed profiles of players operating in global meningitis vaccines market are also provided in the report, which highlight company description, overview, product/segment overview, SWOT analysis, financial information, key developments related to the market and a strategic overview.

The next section of report analyses the market based on product types and presents the forecast in terms of value for the next 10 years. Meningococcal vaccine product types covered in the report include:

  • Polysaccharide Vaccines

  • Conjugate Vaccines

The next section of the report analyses the market based on age group and provides forecast in terms of value for the next 10 years. Based on age groups, the global market has been segmented in to

  • Infants

  • Children

  • Adolescents & Young Adults

  • Adults

The next section of the report analyses the market based on distribution channel for meningococcal vaccine products and provides forecast in terms of value for the next 10 years. Distribution channels covered in this report are:

  • Pharmacies

  • Community Clinics

  • Public Health Agencies

  • Others (hospital pharmacy, private market etc.)

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective. To understand key growth segments, Future Market Insights provides the ‘Attractiveness Index’ analysis to help clients identify real market opportunities.

COVID -19 : Impact Analysis

Request the coronavirus impact analysis across industries and markets

Request Covid -19 Impact

Get in touch

Harish Tiwari

Global Head - Business Development

Akshay Godge

Client Partner - Global Business Development

Our Clients


See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Request Sample Ask An Analyst Request Special Price Request Methodology